Portal de Periódicos da CAPES

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy

2015; Elsevier BV; Volume: 125; Issue: 14 Linguagem: Inglês

10.1182/blood-2014-12-619163

1528-0020

Martin F. M. de Rooij, Annemieke Kuil, Arnon P. Kater, Marie José Kersten, Steven T. Pals, Marcel Spaargaren,

Chronic Myeloid Leukemia Treatments

To the editor: Most B-cell malignancies are dependent upon signaling by the B-cell receptor (BCR) and other growth and survival signals provided by the tumor microenvironment. Two recently US Food and Drug Administration–approved drugs that target the BCR signalosome, the Bruton tyrosine kinase (